Skip to main content
* indicates a required field

Welcome to the Submission Site

The following information is required in order to submit an abstract. Submitters must create a login with their first name, last name, and email address. Submitters can be the Presenting Author or another individual submitting on behalf of the Presenting Author. The Submitter must provide complete contact information (full name, degree, institution, address, telephone number, email address) in the Abstract Submission System. The Submitter will receive all correspondence from iwCLL regarding the status of the abstract, instructions regarding presentation and publishing. Submitters may also upload a profile picture and brief biography that will be included on the mobile app. These are not mandatory but recommended.

Submitters must also provide co-author information on the first page of the Abstract Submission System. IMPORTANT: Author and Co-author details should be excluded from the abstract upload.

Submitters will be unable to save a draft and return to complete the submission, so please be prepared with all the below information upon submission. Submissions will be editable prior to the June deadline date when you log back into the Abstract Submission System. For each submission, the following is mandatory:
  • Abstract Title (300 character limit, including spaces)
  • Abstract Text
  • 700 word limit (abstract body only, excluding title)
  • May include two (2) tables, figures, graphs, or images
  • The uploads of the tables/images may not be larger than 10 MB
  • Structure is permitted, but not required: Introduction, Methods, Results and Conclusions
  • Multiple paragraphs are permitted
  • References are to be cited within the text, not as footnotes
  • Abstracts must be in English
Identification of which meeting submission is intended for:
  1. Young Investigator Meeting
  2. IwCLL Main Meeting
  3. Both Young Investigator Meeting & IwCLL Main Meeting
Abstract Type
General Abstract: All types of clinical-based and laboratory-based research projects relating to CLL and related B-cell lymphoproliferative disorders are eligible for submission.

Encore: Abstracts containing updated data with respect to a previous presentation may be submitted. Authors must supply information regarding the original presentation for identification and comparison purposes, indicating the name of the meeting, year and/or publication number. Abstracts will NOT be accepted if published or presented prior to December 1, 2020.

Trials In Progress: Indicate if the trial has been registered, the registry, and the registration number.

Please select one of the below that your abstract is related to. The category will be used as the initial basis for review of your abstract.
  • Laboratory based research
  • Clinical-based research
  • Real world evidence
Please select one of the below main topics that your abstract is related to. Topics will be used to best place selected abstracts within the program agenda.

Pathogenesis of CLL
  • Molecular Pathogenesis of CLL - Genomics and Proteomics
  • Molecular Pathogenesis of CLL - Microenvironment and Signaling
  • Clonal Dynamics, Competition, and Disease Evolution
Approach considerations and treatment options in CLL
  • Prognostication and Prediction in the Era of Novel Drugs
  • MRD - Methods and Clinical Application
  • First-line therapy of CLL
  • Treatment of relapsed/refractory CLL
Rationally Designed Therapy on the Horizon in CLL
  • New Agents in CLL Clinical Trials
  • Immunotherapy of CLL
Other optional submission questions:
  • Keywords (leukemia, relapsed/refractory, biomarker, etc)
  • Research funding

Log in to the Abstract ScoreCard

Questions? Organizer: Aimee Harwood -